Andere talen Isofol Medical AB

Aandelen

ISOFOL

SE0009581051

Vertraagde tijd Nasdaq Stockholm Andere beurzen 15:50:43 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,722 ^SEK	-2,30%		-0,96%	-1,10%

20/02	Isofol Medical AB (publ) rapporteert resultaten voor het vierde kwartaal dat eindigde op 31 december 2023	CI
20/02	Isofol Medical AB (publ) rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023	16/04
Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)	05/04
Isofol Medical : Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	19/03
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	19/03
Isofol presents a clinical development plan for arfolitixorin	19/03
Isofol Medical : invites to investor meeting on March 19	01/03
Isofol Medical AB (publ) publishes year-end report, January - December 2023	20/02
Isofol Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/02
Isofol Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023	20/02
Isofol's Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19	14/02
Isofol Medical Hires New CFO	11/01
Isofol appoints Magnus Hurst as new Chief Financial Officer	10/01
Isofol Medical AB Announces Chief Financial Officer Changes	10/01
Isofol Medical Names New CEO	09/01
Isofol appoints Petter Segelman Lindqvist as new CEO	09/01
Isofol Medical AB Announces CEO Changes	09/01
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024	04/01
Isofol Medical AB Announces Board Elections	04/01
Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects	28/12
Isofol Medical AB Presents Additional Results from Laboratory Tests with Arfolitixorin Showing Supplementary Effects	28/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Isofol Medical AB

Aandelen

ISOFOL

SE0009581051

Andere talen

Filters